The stock price of AC Immune SA (NASDAQ: ACIU) has jumped by 18.37 compared to previous close of 3.13. Despite this, the company has seen a gain of 13.30% in its stock price over the last five trading days. benzinga.com reported 2024-11-14 that AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease.
Is It Worth Investing in AC Immune SA (NASDAQ: ACIU) Right Now?
The stock has a 36-month beta value of 1.23. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACIU is 61.76M, and at present, short sellers hold a 1.59% of that float. On November 14, 2024, the average trading volume of ACIU was 93.16K shares.
ACIU’s Market Performance
ACIU stock saw an increase of 13.30% in the past week, with a monthly gain of 16.14% and a quarterly increase of 9.94%. The volatility ratio for the week is 5.46%, and the volatility levels for the last 30 days are 5.54% for AC Immune SA (ACIU). The simple moving average for the last 20 days is 19.47% for ACIU’s stock, with a simple moving average of 10.75% for the last 200 days.
Analysts’ Opinion of ACIU
Many brokerage firms have already submitted their reports for ACIU stocks, with BTIG Research repeating the rating for ACIU by listing it as a “Buy.” The predicted price for ACIU in the upcoming period, according to BTIG Research is $8 based on the research report published on May 31, 2024 of the current year 2024.
ACIU Trading at 12.94% from the 50-Day Moving Average
After a stumble in the market that brought ACIU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.92% of loss for the given period.
Volatility was left at 5.54%, however, over the last 30 days, the volatility rate increased by 5.46%, as shares surge +10.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.15% upper at present.
During the last 5 trading sessions, ACIU rose by +8.56%, which changed the moving average for the period of 200-days by +10.59% in comparison to the 20-day moving average, which settled at $3.09. In addition, AC Immune SA saw -25.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACIU starting from ANDREA M. A PFEIFER, who proposed sale 40,000 shares at the price of $3.70 back on Sep 27 ’24. After this action, ANDREA M. A PFEIFER now owns shares of AC Immune SA, valued at $148,000 using the latest closing price.
ANDREA M. A PFEIFER, the Officer of AC Immune SA, proposed sale 20,000 shares at $3.46 during a trade that took place back on Sep 18 ’24, which means that ANDREA M. A PFEIFER is holding shares at $69,200 based on the most recent closing price.
Stock Fundamentals for ACIU
Current profitability levels for the company are sitting at:
- -0.91 for the present operating margin
- -0.15 for the gross margin
The net margin for AC Immune SA stands at -0.97. The total capital return value is set at -0.26. Equity return is now at value -30.57, with -20.00 for asset returns.
Currently, EBITDA for the company is -51.83 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of 7.53. The receivables turnover for the company is 1.56for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.86.
Conclusion
To sum up, AC Immune SA (ACIU) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
